Liebe >LAMP< Freunde auch >CALY< mit TOP NEWS - 500 Beiträge pro Seite
eröffnet am 08.03.02 14:20:53 von
neuester Beitrag 11.03.02 15:41:34 von
neuester Beitrag 11.03.02 15:41:34 von
Beiträge: 10
ID: 562.899
ID: 562.899
Aufrufe heute: 0
Gesamt: 746
Gesamt: 746
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 42 Minuten | 7888 | |
| vor 34 Minuten | 5021 | |
| vor 1 Stunde | 2630 | |
| vor 1 Stunde | 2620 | |
| vor 1 Stunde | 2348 | |
| vor 39 Minuten | 2089 | |
| vor 55 Minuten | 2040 | |
| vor 53 Minuten | 1787 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.843,09 | -1,36 | 239 | |||
| 2. | 3. | 162,72 | +0,36 | 94 | |||
| 3. | 2. | 9,0800 | -5,86 | 90 | |||
| 4. | 4. | 0,1915 | -1,29 | 84 | |||
| 5. | 6. | 0,0330 | +56,40 | 52 | |||
| 6. | 14. | 6,8800 | +2,11 | 51 | |||
| 7. | 34. | 0,6400 | -54,29 | 49 | |||
| 8. | 13. | 426,96 | -13,48 | 47 |
Feedback
Thursday March 7, 7:46 pm Eastern Time
Press Release
SOURCE: Calypte Biomedical Corporation
University of North Carolina Selects Calypte`s Urine Test for International HIV/AIDS Testing Effort
ALAMEDA, Calif.--(BW HealthWire)--March 7, 2002--Calypte Biomedical Corporation (OTCBB:CALY - news), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today announced that the University of North Carolina`s, Department of Medicine, Division of Infectious Diseases, will begin utilizing the urine HIV-1 antibody tests for an international community-based study.
``We performed an evaluation of Calypte`s urine test on known positive and negative samples and verified reliable performance with 100% sensitivity and 100% specificity,`` said Irving Hoffman, director of International Operations at the Division of Infectious Diseases. ``Given the favorable performance of the urine test, we believe the added convenience and client acceptance of urine testing will greatly enhance our ability to screen at risk populations in non-clinic based settings,`` Mr. Hoffman observed. The Department of Medicine at the University of North Carolina is engaged in the fight against the spread of HIV/AIDS in many international locations. Starting in March, the Calypte urine tests will be used as the biological marker in a community-based survey that will study perceived risk of HIV infection and pregnancy in rural Malawi, Africa.
``By one global estimate,`` said Calypte President & CEO Nancy Katz, ``there are 40 million people now living with HIV/AIDS. There were more than 5 million people newly infected with HIV in 2001 and 3 million adults and children lost their lives to AIDS worldwide during that period. Many of those currently living with HIV/AIDS do not even know that they carry the virus. We are very pleased that our urine test was selected by the University of North Carolina for this important effort.``
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, Calif., is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Gruß
Andy
P.S.
WKN von Calypte 909 402
Press Release
SOURCE: Calypte Biomedical Corporation
University of North Carolina Selects Calypte`s Urine Test for International HIV/AIDS Testing Effort
ALAMEDA, Calif.--(BW HealthWire)--March 7, 2002--Calypte Biomedical Corporation (OTCBB:CALY - news), a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services, today announced that the University of North Carolina`s, Department of Medicine, Division of Infectious Diseases, will begin utilizing the urine HIV-1 antibody tests for an international community-based study.
``We performed an evaluation of Calypte`s urine test on known positive and negative samples and verified reliable performance with 100% sensitivity and 100% specificity,`` said Irving Hoffman, director of International Operations at the Division of Infectious Diseases. ``Given the favorable performance of the urine test, we believe the added convenience and client acceptance of urine testing will greatly enhance our ability to screen at risk populations in non-clinic based settings,`` Mr. Hoffman observed. The Department of Medicine at the University of North Carolina is engaged in the fight against the spread of HIV/AIDS in many international locations. Starting in March, the Calypte urine tests will be used as the biological marker in a community-based survey that will study perceived risk of HIV infection and pregnancy in rural Malawi, Africa.
``By one global estimate,`` said Calypte President & CEO Nancy Katz, ``there are 40 million people now living with HIV/AIDS. There were more than 5 million people newly infected with HIV in 2001 and 3 million adults and children lost their lives to AIDS worldwide during that period. Many of those currently living with HIV/AIDS do not even know that they carry the virus. We are very pleased that our urine test was selected by the University of North Carolina for this important effort.``
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, Calif., is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte`s tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners.
Gruß
Andy
P.S.
WKN von Calypte 909 402
....auch in FRankfurt und Berlin handelbar das Ding!
CALY hält sich schön auf dem Level 0,17-0,25 sit vielen Wochen!
Bei wirklich zündenden News stünde einem gewaltigen ausbruch nix mehr im Wege!
morchel
CALY hält sich schön auf dem Level 0,17-0,25 sit vielen Wochen!
Bei wirklich zündenden News stünde einem gewaltigen ausbruch nix mehr im Wege!
morchel
@morchel
Ich habe mich schön eingedeckt
Good Games
Ich habe mich schön eingedeckt
Good Games
bin ebenfalls in CALY investiert.
na, da warten wir mal die dinge ab.
viel erfolg
michaoj
na, da warten wir mal die dinge ab.
viel erfolg
michaoj
@ Hi @ALL
Schön mit CALY und LAMP im Depot.
Bio Spritzen mit high speed
Andy
Schön mit CALY und LAMP im Depot.
Bio Spritzen mit high speed
Andy
Trading Spotlight
So weit ich aus dem Gedächtnis weiß kommt CALY ja von der NASDAQ oder?
morchel
morchel
JA und da wolln se wieder hin
ABER
Morchel
Kaufe noch SPAZ sofern Du CASH hast
Noch im März machen die 1000%
Die News der CeBit werden ein Kracher
Aktuell 0,17
Ziel 1,7
Andy
ABER
Morchel
Kaufe noch SPAZ sofern Du CASH hast
Noch im März machen die 1000%
Die News der CeBit werden ein Kracher
Aktuell 0,17
Ziel 1,7
Andy
Ist Spaz auch in D handelbar 
TomSec
Ja aber schön mit Limit in Frankfurt kaufen.
Spatializer hat folgende:
WKN 892 725
----
zu CALY
Es sieht gut aus
Wenn CALY startet ist kein halten mehr angesagt.
MfG
Andy
Ja aber schön mit Limit in Frankfurt kaufen.
Spatializer hat folgende:
WKN 892 725
----
zu CALY
Es sieht gut aus
Wenn CALY startet ist kein halten mehr angesagt.
MfG
Andy
CALY hebt ab
Time & Sales most recent back next
CALYPTE BIOMEDICAL - OTC BB: CALY
Rec. Time Action Price Volume Exch.
9:38:25 AM Trade (at Ask) 0.23 5000 OTC BB
9:35:56 AM Trade (at Ask) 0.23 1000 OTC BB
9:33:57 AM Trade (at Ask) 0.23 15000 OTC BB
9:33:55 AM Trade (at Ask) 0.23 500 OTC BB
9:33:46 AM Trade (at Ask) 0.23 3000 OTC BB
9:32:50 AM Trade (at Ask) 0.23 500 OTC BB
9:32:45 AM Trade (at Ask) 0.23 2000 OTC BB
9:32:20 AM Trade (at Ask) 0.23 6900 OTC BB
Time & Sales most recent back next
CALYPTE BIOMEDICAL - OTC BB: CALY
Rec. Time Action Price Volume Exch.
9:38:25 AM Trade (at Ask) 0.23 5000 OTC BB
9:35:56 AM Trade (at Ask) 0.23 1000 OTC BB
9:33:57 AM Trade (at Ask) 0.23 15000 OTC BB
9:33:55 AM Trade (at Ask) 0.23 500 OTC BB
9:33:46 AM Trade (at Ask) 0.23 3000 OTC BB
9:32:50 AM Trade (at Ask) 0.23 500 OTC BB
9:32:45 AM Trade (at Ask) 0.23 2000 OTC BB
9:32:20 AM Trade (at Ask) 0.23 6900 OTC BB
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 228 | ||
| 96 | ||
| 90 | ||
| 76 | ||
| 53 | ||
| 49 | ||
| 48 | ||
| 44 | ||
| 42 | ||
| 33 |
| Wertpapier | Beiträge | |
|---|---|---|
| 28 | ||
| 27 | ||
| 27 | ||
| 26 | ||
| 26 | ||
| 24 | ||
| 23 | ||
| 22 | ||
| 21 | ||
| 21 |
